Who Paid My Doc
Emily Isaacs
Rheumatology Fort Worth, TX Medical Doctor
NPI 1114927779 CMS profile 322753
5450 Clearfork Main St Ste 230, Fort Worth, TX 76109
General payments
$158,147
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Emily Isaacs of Fort Worth, TX is reported in the CMS Open Payments database as having received $158,147 across 203 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 95th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $15,547 | 12 | |
| 2022 | General | $40,149 | 59 | |
| 2021 | General | $25,987 | 29 | |
| 2020 | General | $20,662 | 26 | |
| 2019 | General | $55,800 | 77 |
Beside peers
- Emily Isaacs
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Emily Isaacs were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Emily Isaacs | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $55,800 | $744 | $153–$2,687 | $163 |
| 2020 | $20,662 | $462 | $98–$2,027 | $114 |
| 2021 | $25,987 | $531 | $101–$2,153 | $132 |
| 2022 | $40,149 | $627 | $125–$2,303 | $149 |
| 2023 | $15,547 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
108
Drug cost
$3,057
Branded share of claims
42.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 15 | $1,266 | |
| Hydroxychloroquine Sulfate | Generic | 22 | $943 | |
| Methotrexate Methotrexate Sodium | Brand | 26 | $490 | |
| Vitamin D2 Ergocalciferol (Vitamin D2) | Brand | 20 | $189 | |
| Prednisone | Generic | 14 | $100 | |
| Diclofenac Sodium | Generic | 11 | $69 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
203 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in Texas
Related records
Rheumatology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.